Amal Therapeutics SA is a spin-off from the University of Geneva. Amal develops KISIMA, its proprietary vaccine technology platform to progress therapeutic vaccines in oncology. KISIMA combines in one single recombinant protein a vector for targeted antigen delivery, a toll like receptor peptide agonist as adjuvant and a chimeric multi-antigenic construct as vaccine. The platform technology is versatile and flexible, adaptable to a large spectrum of antigens, cancer indications and can further be developed to single patient’s tailored cancer medicine.
On July 15, Boehringer Ingelheim acquired Amal for up to €325m.